Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 20, 2002

View Archived Issues

Nautilus Biotech designs improved interferon alfa

Nycomed licenses TransMID from KS Biomedix in Europe

Progen licenses preclinical cancer therapy from Unisearch

Evra birth control patch approved in E.U. and Canada

IND submission scheduled for Hynic-Annexin V

Guidant licenses exclusive rights for everolimus in drug-eluting stents

IND filed for rhFXIII in patients with congenital FXIII deficiency

AP-23675 discovered for primary bone cancers and bone metastases

Pilot study for argatroban + tPA in acute ischemic stroke

Anxiolytic-like effects seen for NK1 receptor antagonist NKP-608 in gerbils

New option available for patients with hypertension and diabetic kidney disease

Promising results obtained with BBR-2778 in animal models of MS

Deligoparin does not meet endpoints of pivotal study in ulcerative colitis

Novartis exercises option to license back oral renin inhibitor

Copper chelator exerts antiangiogenic effects via suppression of NF-kB activity

VX-148: a novel IMP dehydrogenase inhibitor with a favorable preclinical profile

Nabi and U. of Maryland researchers identify compounds with broad antiinfective activity

New PDE4 inhibitors designed by Ono

Theravance describes multibinding H1 antagonists for allergic rhinitis and other uses

Novel antiplatelet agents with dual sGC-activating and PDE-inhibitory activity

IPD discloses aldose reductase inhibitors and their use in diabetic complications

Takeda identifies new series of cephem antibiotics

Pfizer returns rights to Onyx products

Broad-spectrum antiviral compounds disclosed in Shire BioChem patent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Rare earth: Biomarin to use global reach post-$4.8B Amicus buy
BioWorld
Biomarin Pharmaceutical Inc. followed up its May takeover of Inozyme Pharma Inc. with a much larger agreement to acquire Amicus Therapeutics Inc. for $14.50 per...